Current Report Filing (8-k)
December 08 2014 - 12:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 8, 2014
ONCOSEC MEDICAL INCORPORATED
(Exact name of registrant as specified in its charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
9810 Summers Ridge Road, Suite 110 San Diego, California |
|
92121 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (855) 662-6732
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On December 8, 2014, OncoSec Medical Incorporated (the Company) issued a press release regarding the Companys financial results for the three months ended October 31, 2014. A copy of the Companys press release containing this information is being furnished as Exhibit 99.1 to this Current Report.
The information in this Current Report, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing to this Current Report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
Description |
99.1 |
|
OncoSec Medical Incorporated press release dated December 8, 2014 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ONCOSEC MEDICAL INCORPORATED |
|
|
|
Dated: December 8, 2014 |
By: |
/s/ Punit Dhillon |
|
|
Name: Punit Dhillon |
|
|
Title: President & Chief Executive Officer |
2
Exhibit 99.1
OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015
SAN DIEGO December 8, 2014 OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
FINANCIAL RESULTS
For the quarter ended October 31, 2014, OncoSec Medical reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.
Research and development expenses were $2.5 million for the quarter ended October 31, 2014, compared to $0.8 million for the quarter ended October 31, 2013. This increase in research and development expenses was primarily a result of increased salary related expenses, increased outside services costs and increased lab supplies as we further expand our internal research capabilities and further our research of next-generation devices, novel electroporation technologies and combination studies.
General and administrative expenses were $1.6 million for the quarter ended October 31, 2014, compared to $1.2 million for the quarter ended October 31, 2013. This increase in general and administrative expenses was primarily a result of increased salary related expenses due to increased headcount to support the growth in our operations, offset by a savings in legal services costs.
At October 31, 2014, we had $34.0 million in cash and cash equivalents, as compared to $37.9 million of cash and cash equivalents at July 31, 2014. We expect these funds to be sufficient to allow us to continue to operate our business for at least the next 12 months.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medicals core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSecs lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such forward-looking statements. Forward-looking statements are based on managements current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medicals filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Public Relations:
Laura Radocaj
Dian Griesel Intl.
212-825-3210
lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024